42 related articles for article (PubMed ID: 19497367)
1. Examination of potential mechanisms of amyloid-induced defects in neuronal transport.
Shah SB; Nolan R; Davis E; Stokin GB; Niesman I; Canto I; Glabe C; Goldstein LS
Neurobiol Dis; 2009 Oct; 36(1):11-25. PubMed ID: 19497367
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane.
Zhang L; Trushin S; Christensen TA; Tripathi U; Hong C; Geroux RE; Howell KG; Poduslo JF; Trushina E
Neurobiol Dis; 2018 Jun; 114():1-16. PubMed ID: 29477640
[TBL] [Abstract][Full Text] [Related]
3. Axonal transport defects in neurodegenerative diseases.
Morfini GA; Burns M; Binder LI; Kanaan NM; LaPointe N; Bosco DA; Brown RH; Brown H; Tiwari A; Hayward L; Edgar J; Nave KA; Garberrn J; Atagi Y; Song Y; Pigino G; Brady ST
J Neurosci; 2009 Oct; 29(41):12776-86. PubMed ID: 19828789
[TBL] [Abstract][Full Text] [Related]
4. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
Zhang H; Wei W; Zhao M; Ma L; Jiang X; Pei H; Cao Y; Li H
Int J Biol Sci; 2021; 17(9):2181-2192. PubMed ID: 34239348
[TBL] [Abstract][Full Text] [Related]
5. Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.
Majid T; Griffin D; Criss Z; Jarpe M; Pautler RG
Alzheimers Dement (N Y); 2015 Nov; 1(3):170-181. PubMed ID: 29854936
[TBL] [Abstract][Full Text] [Related]
6. White matter hyperintensity microstructure in amyloid dysmetabolism.
Kalheim LF; Bjørnerud A; Fladby T; Vegge K; Selnes P
J Cereb Blood Flow Metab; 2017 Jan; 37(1):356-365. PubMed ID: 26792028
[TBL] [Abstract][Full Text] [Related]
7. Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesis.
Meeker RB; Poulton W; Clary G; Schriver M; Longo FM
Exp Neurol; 2016 Jan; 275 Pt 1(0 1):182-98. PubMed ID: 26424436
[TBL] [Abstract][Full Text] [Related]
8. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques.
Gowrishankar S; Yuan P; Wu Y; Schrag M; Paradise S; Grutzendler J; De Camilli P; Ferguson SM
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):E3699-708. PubMed ID: 26124111
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of neurofilament 200 and amyloid-β peptide (1-40) in a rat model of chronic cerebral hypoperfusion.
Liang W; Zhang W; Zhao S; Li Q; Liang H; Ceng R
Neurol Sci; 2015 May; 36(5):707-12. PubMed ID: 25452168
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function.
Ari C; Borysov SI; Wu J; Padmanabhan J; Potter H
Neurobiol Aging; 2014 Aug; 35(8):1839-49. PubMed ID: 24636920
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones promote axonal growth through the activation of the JNK pathway.
Quintanilla RA; Godoy JA; Alfaro I; Cabezas D; von Bernhardi R; Bronfman M; Inestrosa NC
PLoS One; 2013; 8(5):e65140. PubMed ID: 23741474
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.
Gunawardena S
Pharm Res; 2013 Oct; 30(10):2459-74. PubMed ID: 23625095
[TBL] [Abstract][Full Text] [Related]
13. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid.
Nath S; Agholme L; Kurudenkandy FR; Granseth B; Marcusson J; Hallbeck M
J Neurosci; 2012 Jun; 32(26):8767-77. PubMed ID: 22745479
[TBL] [Abstract][Full Text] [Related]
14. Neuronal and vascular oxidative stress in Alzheimer's disease.
Massaad CA
Curr Neuropharmacol; 2011 Dec; 9(4):662-73. PubMed ID: 22654724
[TBL] [Abstract][Full Text] [Related]
15. Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI.
Gallagher JJ; Zhang X; Ziomek GJ; Jacobs RE; Bearer EL
Neuroimage; 2012 Apr; 60(3):1856-66. PubMed ID: 22500926
[TBL] [Abstract][Full Text] [Related]
16. Axonal transport and neurodegenerative disease: can we see the elephant?
Goldstein LS
Prog Neurobiol; 2012 Dec; 99(3):186-90. PubMed ID: 22484448
[TBL] [Abstract][Full Text] [Related]
17. Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.
Solomon JP; Page LJ; Balch WE; Kelly JW
Crit Rev Biochem Mol Biol; 2012; 47(3):282-96. PubMed ID: 22360545
[TBL] [Abstract][Full Text] [Related]
18. Glial-derived prodegenerative signaling in the Drosophila neuromuscular system.
Keller LC; Cheng L; Locke CJ; Müller M; Fetter RD; Davis GW
Neuron; 2011 Dec; 72(5):760-75. PubMed ID: 22153373
[TBL] [Abstract][Full Text] [Related]
19. GSK3β is involved in the relief of mitochondria pausing in a Tau-dependent manner.
Llorens-Martín M; López-Doménech G; Soriano E; Avila J
PLoS One; 2011; 6(11):e27686. PubMed ID: 22110721
[TBL] [Abstract][Full Text] [Related]
20. Submicromolar Aβ42 reduces hippocampal glutamate receptors and presynaptic markers in an aggregation-dependent manner.
Wisniewski ML; Hwang J; Bahr BA
Biochim Biophys Acta; 2011 Dec; 1812(12):1664-74. PubMed ID: 21978994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
